Female patients, if of childbearing potential, must have a negative serum pregnancy test within 72 hours prior to the date of the first dose of study medication.
Women of childbearing potential must have a negative serum or urine pregnancy test within 96 hours prior to start of study drug.
For women of childbearing potential (defined as women with menses within the past 2 years), a negative serum pregnancy test must be documented prior to registration; NOTE: in addition to screening, serum pregnancy test must be performed on females of childbearing potential within 72 hours before the start of investigational product; when possible, these tests can be one-in-the-same (if screening pregnancy test was performed within 72 hours of first ponatinib dose, no need to repeat)
Women of childbearing potential must have negative pregnancy test within 24 hours of enrollment
Female participants of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study drug
Patient (of childbearing potential) is not breastfeeding, has a negative serum pregnancy test within 72 hours prior to taking study drug, and agrees to abstain from activities that could result in pregnancy from Screening through 180 days after the last dose of study drug, or is of nonchildbearing potential.
Female participants of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study therapy
Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication.
Negative serum or urine pregnancy test for women within 72 hours of receiving the first dose of the study medication for women of childbearing potential.
Women of childbearing potential must have a negative pregnancy test within 72 hours prior to receiving the first dose of study medication
Pregnant or nursing women. \r\n* NOTE: Women of reproductive potential must have a negative serum pregnancy test performed within 48 hours of starting conditioning chemotherapy
Female participants of childbearing potential must have a negative serum pregnancy within 72 hours prior to enrollment
Women of childbearing potential must have a negative serum pregnancy test at screening and =< 72 hours prior to day 1 of study treatment
Women of childbearing potential must have a negative serum or urine pregnancy test within 48 hours prior to the start of nivolumab.
Pregnant or nursing women; NOTE: Women of reproductive potential must have a negative serum pregnancy test performed within 48 hours of starting conditioning chemotherapy
Female participants of childbearing potential should have a negative serum pregnancy test within 24 hours prior to receiving first dose of trial medication.
Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study medication
have a negative urine pregnancy test within 24 hours prior to the first dose of study treatment, and
Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first dose of pembrolizumab
For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication
Female subject of childbearing potential should have a negative serum pregnancy testing at screening visit and within 72 hours prior to the first dose of study medication
Female subject of childbearing potential should have a negative serum pregnancy within 48 hours prior to receiving the first dose of study medication
Negative serum pregnancy test for women of childbearing potential =< 7 days prior to registration; Note: a second pregnancy test may be required =< 72 hours prior to receiving the first dose of study medication
Women of childbearing potential also may not be breast feeding and must have a negative serum or urine pregnancy test within 72 hours before the start of study treatment
Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the start of nivolumab
Females of child-bearing potential (not surgically sterilized or postmenopausal [a woman who is >= 45 years of age and has not had menses for greater than 1 year]) must test negative for pregnancy within 48 hours prior to any initial study procedure based on a serum pregnancy test; both sexually active males and females of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and their health care team, during the study and for 120 days following the last dose of study drug; if subject uses appropriate contraceptive methods (the use of two forms at the same time) from the time of the initial serum pregnancy test, then the subsequent pregnancy test can be done within 72 hours of receiving study drug administration; if appropriate; contraceptive measures are not begun immediately with the first serum pregnancy test, then subsequent serum pregnancy tests must be done within 48 hours prior to the study drug administration
Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of IRX5183
Negative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potential
PRIOR TO LYMPHODEPLETION: For WOCBP negative serum pregnancy test within 72 hours prior to lymphodepletion
Women of childbearing potential (defined as having a menstrual cycle within the past 12 months and not having had a surgical procedure to accomplish sterilization) must have a negative serum pregnancy test within seven days of screening and within 24 hours prior to the start of each nivolumab dose
Pregnant or lactating women; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
Negative serum or urine pregnancy test for women within 72 hours of receiving the first dose of the study medication for women of childbearing potential
Women of childbearing potential (WOCBP) must have negative pregnancy test within 72 hours prior to day (D)1 of treatment
Negative serum or urine pregnancy test for women within 72 hours of receiving the first dose of the study medication for women of childbearing potential
For women of childbearing potential only: Negative pregnancy test =< 10-14 days prior to registration; NOTE: the patient must have an additional negative pregnancy test =< 24 hours prior to receiving the initial prescription of lenalidomide, per requirements of the REVLIMID Risk Evaluation and Mitigation Strategies (REMS) program
Female subject's of childbearing potential must have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication
Negative serum or urine pregnancy test within 72 hours of commencement of treatment in premenopausal women
Pregnant or nursing (lactating) women, female study participants of reproductive potential must have a negative serum or urine pregnancy test within 48 hours before infusion
Pregnant or lactating women; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
Negative serum pregnancy test with 72 hours prior to start of study drug
Negative serum pregnancy test within 72 hours prior to the first study dose in all women of childbearing potential
Women of child-bearing potential must have a negative serum pregnancy test at screening; in addition to having a negative pregnancy test confirmed at screening, all female participants of childbearing potential must have a negative pregnancy test confirmed within 48 hours prior to dosing with the study drug
Negative serum or urine pregnancy test within 72 hours prior to registration for women of childbearing potential
Women of child-bearing potential must have a negative serum pregnancy test during Screening and a negative urine pregnancy test within 24 hours prior to first dose of study treatment. Non-childbearing is defined as greater than one year postmenopausal or surgically sterilized.
Negative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potential
WOCBP must have a negative pregnancy test within 24 hours prior to Study Day 0.
Female subjects of childbearing potential should have a negative serum pregnancy test within 72 hours of starting first dose of study drug.
A woman of childbearing potential must have a negative serum or urine pregnancy test at screening within 14 days and again within 72 hours prior to dosing
Female patients with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 72 hours prior to administration of any treatment
Serum pregnancy test for female patients of childbearing potential, =< 72 hours prior to study entry; women of childbearing potential and male participants must practice adequate contraception
Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential
For women of childbearing potential, a serum pregnancy test within 72 hours prior to registration
Negative serum pregnancy test within 48 hours before starting study treatment in women with childbearing potential
Patients of childbearing potential must have negative pregnancy serum test within 72 hours of being dosed
Female participants of childbearing potential must have 2 negative urine pregnancy tests (with a sensitivity of at least 25 Milli-international units/Milliliter) within 10 to 14 days and within 24 hours prior to receiving study medication.
Female patient, if of childbearing potential, has a negative serum pregnancy test within 72 hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment
Patients of childbearing potential must have negative pregnancy serum test within 72 hours of being dosed
Pregnant or nursing (lactating) women. NOTE: female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
Pregnant or lactating women; female study participants of reproductive potential must have a negative serum pregnancy test at enrollment; a urine or serum pregnancy test will be performed within 48 hours before the RNA CART19 infusion
Serum pregnancy test for female patients of childbearing potential, =< 72 hours prior to study entry; women of childbearing potential and male participants must practice adequate contraception
Women of childbearing potential must have a negative serum pregnancy test within the 14-day period prior to randomization. (Where demanded by local regulations, this test may be required within 72 hours of randomization.)
Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential
Females of child-bearing potential (not surgically sterilized and between menarche and 1 year post menopause) must test negative for pregnancy within 48 hours prior to any initial study procedure based on a serum pregnancy test; both sexually active males and females of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and their health care team, during the study and for 3 months following the last dose of study drug; if subject uses appropriate contraceptive methods (the use of two forms at the same time) from the time of the initial serum pregnancy test, then the subsequent pregnancy test can be done within 72 hours of receiving study drug administration; if appropriate contraceptive measures are not begun immediately with the first serum pregnancy test, then subsequent serum pregnancy tests must be done within 48 hours prior to the study drug administration
Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential
Women of childbearing potential must have a negative serum pregnancy test during Screening Period and within 48 hours of the first dose of ARQ 087.
Pregnant or lactating women; the safety of this therapy on unborn children is not known; female study participants of reproductive potential must have a negative serum or urine pregnancy test performed within 48 hours before infusion
For females of childbearing potential, a serum pregnancy test within 2 weeks prior to registration; note: if pelvic irradiation is to be given, the serum pregnancy test must be repeated within 48 hours prior to registration
Female subject of childbearing potential must have a negative serum pregnancy 10-14 days prior to registration, and again within 24 hours prior to the first dose of lenalidomide
For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication
Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential
Female subjects of childbearing potential must have a negative serum pregnancy test at screening within 96 hours prior to the first study dose.
Women of childbearing potential must have a negative pregnancy test performed within 48 hours prior to the start of the study drug
Female patient of childbearing potential should have a negative urine or serum pregnancy test within 72 hours.
For women of childbearing potential, a negative serum or urine pregnancy test with sensitivity less than 50 mIU/m within 72 hours before the start of study medication
Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 10 to 14 days and again within 24 hours of starting study drug
Female patient has a negative serum pregnancy test within 72 hours prior to taking study drug if of childbearing potential, and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment, or be of non-childbearing potential.
Female participants of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study therapy
In women of child-bearing potential (WOCBP), a negative serum pregnancy test within 72 hours prior to procurement and again 72 hours prior to infusion is required
If of childbearing potential, the patient has a negative pregnancy test within 72 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year
Women of childbearing potential (WOCBP) must have a negative pregnancy test (serum or urine) within the 7 days prior to study drug administration, and within the 3 days before the first study drug administration, or a negative pregnancy test within the 24 hours before the first study drug administration.
Positive serum or urine pregnancy test within 24 hours of imaging prior to injection of radiotracer (for women of childbearing potential per Radiology Department clinical guidelines)
If of childbearing potential, the subject has a negative pregnancy test within 48 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year
Negative urine pregnancy test within 36 hours prior to study drug administration, if of childbearing potential
Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 24 hours prior to the restart of study drug
Female subject of childbearing potential should have a negative urine or serum pregnancy test within 72 hours prior to dosing.